Pharma BD Deal Intelligence
Merck's $130M bet on a follow-on biologics/manufacturing platform produced no approved product and was liquidated five years later as part of a cost-cutting restructuring.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FierceBiotech framed the deal as a clear positive for both sides — Merck advanced its newly created BioVentures FOB unit, and Insmed locked in non-dilutive…
Drug Discovery News positioned the transaction as Merck's strategic biosimilars commitment, with $130M securing manufacturing capacity and a pipeline that…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Insmed sold its follow-on biologics (FOB) platform — including the Phase 3 rG-CSF candidate INS-19, the Phase 1 pegylated rG-CSF INS-20, and a Boulder, Colorado biologics manufacturing facility — to Merck for $130 million in gross proceeds, with no further milestone or royalty obligations. The transaction advanced Merck's newly formed BioVentures biosimilars unit while giving Insmed non-dilutive cash to focus on its Iplex program. Announced February 2009.
Merck's $130M bet on a follow-on biologics/manufacturing platform produced no approved product and was liquidated five years later as part of a cost-cutting restructuring.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Insmed Inc. (Follow-on Biologics platform) (this deal) | 2009 | $130M | 16 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2009 deals · Merck & Co. Inc. deals